Keystone Symposia is very pleased to hold our
second rare disease conference and our first conference in a series of annual conferences to be held
in beautiful Vienna, Austria, developed in collaboration with Vienna BioCenter Research Institutes
GMI, IMBA, IMP and MFPL.
Work over the past 30 years has resulted in the identification
of genes for approximately 50% of the estimated 7,000 rare genetic diseases, and 500 medicinal
products are currently on the market for rare diseases. It is predicted that most of the remaining
disease genes will be identified in the next 10 years. The accelerating pace of rare disease gene
identification means, in effect, an almost commensurate increase in molecularly defined, readily
diagnosable, but nonetheless poorly understood and untreatable diseases. The three-day conference
- Examine the current and future bottlenecks to gene
discovery, disease modeling and therapeutic approaches for the estimated 7,000 known rare
- Explore platforms for enabling global cooperation and
data sharing to address the grand challenges of rare diseases;
- Bring together diverse stakeholders (clinicians, basic scientists, industry, government,
patient advocates), as well as students and post-doctoral fellows, to forge cross-disciplinary,
international collaborations to advance rare disease research and
The conference will feature the following confirmed invited
speakers (additional short talk speakers will be added, chosen from
Ardigò, Chiesi Farmaceutici, Italy|
Jasmin Barman-Aksözen, Municipal
Hospital Triemli, Switzerland
Lisa Bastarache, Vanderbilt University Medical
Kym Boycott, CHEO Research Institute, Canada
Boztug, Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases,
Silvia Cappello, Max Planck Institute of Psychiatry,
Helene Cederroth*, Wilhelm Foundation, Sweden
Luca*, University of Modena and Reggio Emilia, Italy
Medical University of Vienna and Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases,
William A. Gahl, NHGRI, National Institutes of Health,
Petra Kaufmann, AveXis, Inc., USA
Ludwig-Maximilians-University Munich, Germany
Jürgen A. Knoblich, IMBA,
Institute of Molecular Biotechnology, Austria
Michael J. Lenardo, NIAID,
National Institutes of Health, USA
Malin Parmar, Wallenberg Neuroscience Center,
Sergiu Pasca, Stanford University, USA
Penninger, Institute of Molecular Biotechnology GmbH, Austria
Pyle, University of California, Los Angeles, USA
Institute of Medical Biology, A*STAR, Singapore
Botond Roska, Friedrich Miescher
Developed in collaboration
Who should attend?
Biotechnologists ? Clinicians
? Developmental Biologists ? Disease Modelers ? Drug Developers ? Geneticists ? Immunologists ?
Neuroscientists ? Regulatory Scientists ? Stem Cell
here to view the program and click
here to download the program flyer.
- Deadlines are
at midnight US Mountain Time.
- Scholarships are for graduate
students and postdocs and fund reimbursement of up to 1,200 USD in conference-related costs.
- Discounted abstract submission saves 50 USD and discounted registration
saves 200 USD on the later fees.
- Presenting a poster is an
excellent way to gain feedback on your work. Abstracts submitted by the August 13 abstract deadline
will be considered for short talks on the program.
- Please note
that the first advertised meeting date is the date of arrival and registration, and the last date
that of the last organized sessions.